SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-401723"
 

Sökning: id:"swepub:oai:DiVA.org:uu-401723" > Metastatic colorect...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004732naa a2200433 4500
001oai:DiVA.org:uu-401723
003SwePub
008200108s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4017232 URI
0247 a https://doi.org/10.1080/0284186X.2019.16912582 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Mezheyeuski, Arturu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)artme913
2451 0a Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy :b a population-based Scandinavian study
264 1b Taylor & Francis,c 2020
338 a electronic2 rdacarrier
520 a Background: Survival and response to therapy in patients with metastatic colorectal cancer (mCRC) are very heterogeneous. There is an unmet need for better markers of prognosis and treatment benefit for mCRC patients. The homeobox 2 gene SATB2 has a highly specific expression in colorectal tissue and is associated with better prognosis in non-metastatic CRC.Material and methods: A population-based cohort of 798 mCRC patients was analysed. From primary tumour material, protein expression was assessed by immunohistochemistry. BRAF and KRAS mutation status was also determined. Associations with clinicopathological data, overall and progression-free survival and response to first-line chemotherapy were analysed.Results: Tumour tissue and clinical data were available from 467 patients. SATB2 was strongly expressed in 58% of cases, significantly more in left-sided, low-grade and wild-type BRAF tumours. Patients with high SATB2 tumours had longer overall survival compared with low SATB2 tumours (median 13 vs 8 months respectively, p < .001). Chemotherapy was given to 282 patients (63%). Patients with high SATB2 tumours had longer OS (median 22 vs 15 months respectively, p = .001) and more often responded to chemotherapy than those with low SATB2 (objective response 43% vs 29%, p = .02; clinical response 83% vs 67%, p = .004). Progression-free survival on first-line irinotecan chemotherapy was longer in high SATB2 cases (median 8 vs 4 months respectively, p = .019). Patients with both low SATB2 expression and mutated BRAF (n = 69) had particularly poor survival compared to the rest (median 8 and 12 months respectively, p = .001). In multivariable analysis, the SATB2 findings were independent of known clinicopathological prognostic markers, including BRAF mutation status.Conclusion: Patients with mCRC expressing high level of SATB2 have better prognosis and response to chemotherapy than those with low SATB2 expression. Patients with both low SATB2 expression and mutated BRAF had particularly poor prognosis and could thus benefit from more aggressive therapies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng
653 a Patologi
653 a Pathology
7001 a Pontén, Fredriku Uppsala universitet,Institutionen för immunologi, genetik och patologi,Fredrik Pontén4 aut0 (Swepub:uu)fredpont
7001 a Edqvist, Per-Henrik Du Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)peedq227
7001 a Sundström, Magnusu Uppsala universitet,Institutionen för immunologi, genetik och patologi,Johan Botling4 aut0 (Swepub:uu)magnsund
7001 a Thunberg, Ulfu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)ulfthunb
7001 a Qvortrup, Camilla4 aut
7001 a Pfeiffer, Per4 aut
7001 a Sorbye, Halfdan4 aut
7001 a Glimelius, Bengtu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)bengglim
7001 a Dragomir, Ancau Uppsala universitet,Institutionen för immunologi, genetik och patologi,Fredrik Pontén4 aut0 (Swepub:uu)ancadrag
7102 a Uppsala universitetb Institutionen för immunologi, genetik och patologi4 org
7730 t Acta Oncologicad : Taylor & Francisg 59:3, s. 284-290q 59:3<284-290x 0284-186Xx 1651-226X
8564 u https://doi.org/10.1080/0284186X.2019.1691258y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1383785/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-401723
8564 8u https://doi.org/10.1080/0284186X.2019.1691258

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy